{"success":true,"data":{"pressRelease":{"id":"104707","rtpr_id":"nPn4ghfxJa","ticker":"7630","exchange":"HKEX","all_tickers":["7630"],"title":"IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand","author":"PR Newswire","published_at":"2026-07-31T07:49:23.511Z","article_body":"IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand\n\nPR Newswire\n\nSHANGHAI, July 31, 2026\n\nSHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics (\"IMPACT\")\n(07630.HK) is pleased to announce that it has entered into an exclusive\npartnership (the \"Exclusive Partnership\") with Pharmanovia, a global specialty\npharmaceutical company which partners with innovative biotech and large pharma\nto bring innovative specialty medicines to patients, to grant Pharmanovia the\nexclusive rights to manufacture, develop and commercialise senaparib in\nEurope, Middle East and North Africa, Australia and New Zealand for\nmaintenance monotherapy for advanced epithelial high-grade ovarian, fallopian\ntube and primary peritoneal cancer.\n\nKEY TRANSACTION HIGHLIGHTS\n * IMPACT is eligible to receive an upfront payment plus near-term regulatory\nmilestones and commercial milestone payments upon achieving certain sales\nthresholds, with a total amount up to EUR423.5 million, and such further\ntiered royalties up to the mid-twenties (%) on product net sales;\n * The Exclusive Partnership expands senaparib's global reach to 66 countries;\nand\n * Marketing Authorisation Application (MAA) of senaparib for 1L maintenance\ntherapy for adult patients with advanced ovarian cancer in Europe was formally\naccepted by the European Medicines Agency (the \"EMA\") in August 2025, with\napproval expected in the second half of 2026.\nUnder the licensing agreement in relation to the Exclusive Partnership, IMPACT\nhas granted exclusive manufacturing, development and commercialisation rights\nof senaparib for maintenance monotherapy for advanced epithelial high-grade\novarian, fallopian tube and primary peritoneal cancer to Pharmanovia in 66\ncountries, including, among others, all 27 European Union member states, as\nwell as the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein,\nAustralia, New Zealand and countries in the Middle East and North Africa.\n\nIMPACT is eligible to receive consideration up to EUR423.5 million in total\nconsideration, comprising an upfront payment plus near-term regulatory\nmilestones and commercial milestone payments upon achieving certain sales\nthresholds, and such further tiered royalties up to the mid-twenties (%) on\nproduct net sales.\n\nThe Exclusive Partnership marks the first step for IMPACT to bring its\nvalidated treatment options to patients outside of China, expanding\nsenaparib's business footprint across Europe, Middle East and North Africa, as\nwell as Australia and New Zealand. IMPACT will work closely with Pharmanovia\nto advance the commercialisation of senaparib in the collaboration\nterritories. By leveraging Pharmanovia's specialist expertise and established\ninfrastructure, we expect senaparib to reach target patients in the\ncollaboration territories more quickly following approval, helping to deliver\nhigh-quality treatment options to address unmet medical needs. This\ncollaboration will not only enhance the brand recognition of the product and\nIMPACT on a global scale, but also further broaden IMPACT's strategic layout\nfor global commercialisation. We expect that this collaboration will have a\npositive and profound impact on our development.\n\nAbout SENAPARIB (IMP4297)\n\nSenaparib is a novel, highly potent PARP1/2 inhibitor independently developed\nby the Company. Its unique molecular structure ensures excellent target\nselectivity and a wide safety window. Senaparib capsules received National\nMedical Products Administration of China (NMPA) approval in January 2025 as a\nfirst-line maintenance therapy for adult patients with advanced epithelial\novarian, fallopian tube, or primary peritoneal cancer achieving complete or\npartial response to platinum-based chemotherapy, and has been subsequently\nincluded in the National Reimbursement Drug List (NRDL) in December 2025. The\nCompany is actively advancing the clinical and regulatory development of\nsenaparib globally. Its Marketing Authorisation Application (MAA) in Europe\nwas formally accepted by the EMA in August 2025, with approval expected in the\nsecond half of 2026. Concurrently, the Company is pursuing life cycle\nmanagement for senaparib, exploring combination therapy opportunities, and\nexpanding into multiple indications.\n\nAbout IMPACT Therapeutics (07630.HK)\n\nFounded in 2009, we are a commercial-stage biotechnology company focused on\nadvancing synthetic lethality (SL)-based precision anti-cancer therapies\nglobally, delivering innovative treatments to address the unmet medical needs\nof cancer patients. IMPACT was successfully listed on the Main Board of The\nStock Exchange of Hong Kong Limited on May 13, 2026 (Stock Code: 07630.HK). We\nhave in-house discovered and developed one of the most comprehensive and\nadvanced SL franchises and are one of only three companies with both\ncommercial-stage PARP1/2 inhibitors and clinical-stage next-generation\nPARP1-selective inhibitors worldwide.\n\nOur core product, senaparib (IMP4297), has already been commercialized,\nfollowing its approval as 1L maintenance therapy for OC \"all-comers\" in China\nin January 2025, and is reimbursable for OC 1L \"all-comers\" since January 1,\n2026. Senaparib also delivered the most favorable PFS outcome among PARP1/2\ninhibitors (non head-to-head) for 1L maintenance therapy for OC \"all-comers\"\nin China, setting a new benchmark in this class.\n\nOur major pipeline assets include the PARP1/2 inhibitor senaparib (IMP4297),\nPARP1-selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon\nTherapeutics), ATR inhibitor (IMP9064), WEE1 inhibitor (IMP7068), and multiple\nother synthetic lethality target inhibitors.\n\nOur continued growth is powered by an integrated R&D platform that enables\ninnovation across both small molecules and emerging modalities, including ADCs\nand degraders. Additionally, we have forged partnerships with leading global\nbiotech and China pharmaceutical companies to date, as validation of our\npipeline and R&D platform.\n\nAbout Pharmanovia\n\nPharmanovia is a global specialty pharmaceutical company focused on innovative\nspecialty medicines and trusted established brands. Pharmanovia combines\nscientific, medical, regulatory, market access, supply chain and commercial\nexpertise to bring medicines to patients. Together, they reflect a business\nbuilt to meet patient needs today while helping shape better outcomes for\ntomorrow.\n\nView original\ncontent:https://www.prnewswire.com/news-releases/impact-therapeutics-signs-exclusive-license-agreement-with-pharmanovia-for-senaparib-in-europe-middle-east-and-north-africa-australia-and-new-zealand-302839850.html\n(https://www.prnewswire.com/news-releases/impact-therapeutics-signs-exclusive-license-agreement-with-pharmanovia-for-senaparib-in-europe-middle-east-and-north-africa-australia-and-new-zealand-302839850.html)\n\nSOURCE IMPACT Therapeutics\n\n\n\nMaggie Sun, manqi.sun@impacttherapeutics.com, + 86 18875065309\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn4ghfxJa","title":"IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand","author":"PR Newswire","ticker":"7630","created":"2026-07-31T07:49:23.511Z","tickers":["7630"],"exchange":"HKEX","article_body":"IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand\n\nPR Newswire\n\nSHANGHAI, July 31, 2026\n\nSHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics (\"IMPACT\")\n(07630.HK) is pleased to announce that it has entered into an exclusive\npartnership (the \"Exclusive Partnership\") with Pharmanovia, a global specialty\npharmaceutical company which partners with innovative biotech and large pharma\nto bring innovative specialty medicines to patients, to grant Pharmanovia the\nexclusive rights to manufacture, develop and commercialise senaparib in\nEurope, Middle East and North Africa, Australia and New Zealand for\nmaintenance monotherapy for advanced epithelial high-grade ovarian, fallopian\ntube and primary peritoneal cancer.\n\nKEY TRANSACTION HIGHLIGHTS\n * IMPACT is eligible to receive an upfront payment plus near-term regulatory\nmilestones and commercial milestone payments upon achieving certain sales\nthresholds, with a total amount up to EUR423.5 million, and such further\ntiered royalties up to the mid-twenties (%) on product net sales;\n * The Exclusive Partnership expands senaparib's global reach to 66 countries;\nand\n * Marketing Authorisation Application (MAA) of senaparib for 1L maintenance\ntherapy for adult patients with advanced ovarian cancer in Europe was formally\naccepted by the European Medicines Agency (the \"EMA\") in August 2025, with\napproval expected in the second half of 2026.\nUnder the licensing agreement in relation to the Exclusive Partnership, IMPACT\nhas granted exclusive manufacturing, development and commercialisation rights\nof senaparib for maintenance monotherapy for advanced epithelial high-grade\novarian, fallopian tube and primary peritoneal cancer to Pharmanovia in 66\ncountries, including, among others, all 27 European Union member states, as\nwell as the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein,\nAustralia, New Zealand and countries in the Middle East and North Africa.\n\nIMPACT is eligible to receive consideration up to EUR423.5 million in total\nconsideration, comprising an upfront payment plus near-term regulatory\nmilestones and commercial milestone payments upon achieving certain sales\nthresholds, and such further tiered royalties up to the mid-twenties (%) on\nproduct net sales.\n\nThe Exclusive Partnership marks the first step for IMPACT to bring its\nvalidated treatment options to patients outside of China, expanding\nsenaparib's business footprint across Europe, Middle East and North Africa, as\nwell as Australia and New Zealand. IMPACT will work closely with Pharmanovia\nto advance the commercialisation of senaparib in the collaboration\nterritories. By leveraging Pharmanovia's specialist expertise and established\ninfrastructure, we expect senaparib to reach target patients in the\ncollaboration territories more quickly following approval, helping to deliver\nhigh-quality treatment options to address unmet medical needs. This\ncollaboration will not only enhance the brand recognition of the product and\nIMPACT on a global scale, but also further broaden IMPACT's strategic layout\nfor global commercialisation. We expect that this collaboration will have a\npositive and profound impact on our development.\n\nAbout SENAPARIB (IMP4297)\n\nSenaparib is a novel, highly potent PARP1/2 inhibitor independently developed\nby the Company. Its unique molecular structure ensures excellent target\nselectivity and a wide safety window. Senaparib capsules received National\nMedical Products Administration of China (NMPA) approval in January 2025 as a\nfirst-line maintenance therapy for adult patients with advanced epithelial\novarian, fallopian tube, or primary peritoneal cancer achieving complete or\npartial response to platinum-based chemotherapy, and has been subsequently\nincluded in the National Reimbursement Drug List (NRDL) in December 2025. The\nCompany is actively advancing the clinical and regulatory development of\nsenaparib globally. Its Marketing Authorisation Application (MAA) in Europe\nwas formally accepted by the EMA in August 2025, with approval expected in the\nsecond half of 2026. Concurrently, the Company is pursuing life cycle\nmanagement for senaparib, exploring combination therapy opportunities, and\nexpanding into multiple indications.\n\nAbout IMPACT Therapeutics (07630.HK)\n\nFounded in 2009, we are a commercial-stage biotechnology company focused on\nadvancing synthetic lethality (SL)-based precision anti-cancer therapies\nglobally, delivering innovative treatments to address the unmet medical needs\nof cancer patients. IMPACT was successfully listed on the Main Board of The\nStock Exchange of Hong Kong Limited on May 13, 2026 (Stock Code: 07630.HK). We\nhave in-house discovered and developed one of the most comprehensive and\nadvanced SL franchises and are one of only three companies with both\ncommercial-stage PARP1/2 inhibitors and clinical-stage next-generation\nPARP1-selective inhibitors worldwide.\n\nOur core product, senaparib (IMP4297), has already been commercialized,\nfollowing its approval as 1L maintenance therapy for OC \"all-comers\" in China\nin January 2025, and is reimbursable for OC 1L \"all-comers\" since January 1,\n2026. Senaparib also delivered the most favorable PFS outcome among PARP1/2\ninhibitors (non head-to-head) for 1L maintenance therapy for OC \"all-comers\"\nin China, setting a new benchmark in this class.\n\nOur major pipeline assets include the PARP1/2 inhibitor senaparib (IMP4297),\nPARP1-selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon\nTherapeutics), ATR inhibitor (IMP9064), WEE1 inhibitor (IMP7068), and multiple\nother synthetic lethality target inhibitors.\n\nOur continued growth is powered by an integrated R&D platform that enables\ninnovation across both small molecules and emerging modalities, including ADCs\nand degraders. Additionally, we have forged partnerships with leading global\nbiotech and China pharmaceutical companies to date, as validation of our\npipeline and R&D platform.\n\nAbout Pharmanovia\n\nPharmanovia is a global specialty pharmaceutical company focused on innovative\nspecialty medicines and trusted established brands. Pharmanovia combines\nscientific, medical, regulatory, market access, supply chain and commercial\nexpertise to bring medicines to patients. Together, they reflect a business\nbuilt to meet patient needs today while helping shape better outcomes for\ntomorrow.\n\nView original\ncontent:https://www.prnewswire.com/news-releases/impact-therapeutics-signs-exclusive-license-agreement-with-pharmanovia-for-senaparib-in-europe-middle-east-and-north-africa-australia-and-new-zealand-302839850.html\n(https://www.prnewswire.com/news-releases/impact-therapeutics-signs-exclusive-license-agreement-with-pharmanovia-for-senaparib-in-europe-middle-east-and-north-africa-australia-and-new-zealand-302839850.html)\n\nSOURCE IMPACT Therapeutics\n\n\n\nMaggie Sun, manqi.sun@impacttherapeutics.com, + 86 18875065309\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-31T07:49:23.557817329Z","server_sent_at_ms":1785484163557},"received_at":"2026-07-31T07:49:23.609Z","source_url":"https://www.prnewswire.com/news-releases/impact-therapeutics-signs-exclusive-license-agreement-with-pharmanovia-for-senaparib-in-europe-middle-east-and-north-africa-australia-and-new-zealand-302839850.html"},"analysis":{"id":"93722","press_release_id":"104707","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"IMPACT Therapeutics entered an exclusive license agreement with Pharmanovia to commercialize Senaparib in Europe, MENA, Australia, and New Zealand.\n\nThe deal covers 66 countries and includes potential milestone payments and royalties totaling up to EUR 423.5 million, leveraging Pharmanovia's established infrastructure.\n\nThe European Medicines Agency accepted the Marketing Authorisation Application for Senaparib in August 2025, with approval expected in the second half of 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"EUR 423.5M potential value deal expands Senaparib to 66 countries."},"keyFigures":{"drugName":"Senaparib","customDimensions":{"royalties":"mid-twenties (%)","territory_count":66,"total_consideration":"EUR 423.5 million"}},"quotedText":"The Exclusive Partnership marks the first step for IMPACT to bring its validated treatment options to patients outside of China","namedEntities":{"people":[{"name":"Maggie Sun"}],"products":["Senaparib","IMP4297","IMP1734","IMP1707","IMP9064","IMP7068"],"companies":[{"name":"IMPACT Therapeutics","ticker":"07630.HK"},{"name":"Pharmanovia","relationship":"partner"},{"name":"Eikon Therapeutics","relationship":"co-developer"},{"name":"European Medicines Agency","relationship":"regulator"}],"dollarAmounts":[{"amount":"EUR423.5 million","context":"total potential consideration from license agreement"}]},"materialImpact":{"score":4,"reasoning":"Exclusive license agreement covering 66 countries with potential consideration up to EUR 423.5 million, significantly validating the asset and expanding global reach for a small-cap biotech."},"tickerRelevance":{"others":[],"primary":"7630"},"globalImportance":30,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"major-partnership","sectorWeight":"biotech"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"IMPACT Therapeutics entered an exclusive license agreement with Pharmanovia to commercialize Senaparib in Europe, MENA, Australia, and New Zealand.\n\nThe deal covers 66 countries and includes potential milestone payments and royalties totaling up to EUR 423.5 million, leveraging Pharmanovia's established infrastructure.\n\nThe European Medicines Agency accepted the Marketing Authorisation Application for Senaparib in August 2025, with approval expected in the second half of 2026.","key_figures":{"drugName":"Senaparib","customDimensions":{"royalties":"mid-twenties (%)","territory_count":66,"total_consideration":"EUR 423.5 million"}},"named_entities":{"people":[{"name":"Maggie Sun"}],"products":["Senaparib","IMP4297","IMP1734","IMP1707","IMP9064","IMP7068"],"companies":[{"name":"IMPACT Therapeutics","ticker":"07630.HK"},{"name":"Pharmanovia","relationship":"partner"},{"name":"Eikon Therapeutics","relationship":"co-developer"},{"name":"European Medicines Agency","relationship":"regulator"}],"dollarAmounts":[{"amount":"EUR423.5 million","context":"total potential consideration from license agreement"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-31T07:53:52.346Z","global_importance":30,"audience_relevance":25,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"major-partnership","sectorWeight":"biotech"}},"durationMs":268727,"modelName":"glm-4.7"}}